The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

A complex relationship links magnesium and cancer. The aim of this review is to revisit
current knowledge concerning the contribution of magnesium to tumorigenesis, from …

Cancer patients may develop a variety of kidney lesions that impair not only their immediate
survival but also limit the adequate treatment of the underlying malignant process. This …

The use of anticancer drugs is beneficial for patients with malignancies but is frequently
associated with the occurrence of electrolyte disorders, which can be hazardous and in …

Background The epidermal growth factor receptor (EGFR) pathway is important in tumor
growth, survival, and metastasis and is now the target of several therapeutic agents …

The advent of the epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies
(mAbs), cetuximab and panitumumab has expanded the range of treatment options for …

Purpose This preclinical and phase II study evaluated the efficacy and safety of the
combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC). Patients and …

Introduction: The typical class side effect of anti-epidermal growth factor receptor (EGFR)
monoclonal antibodies (panitumumab and cetuximab) is a cutaneous maculopapular rash …

As there are no clear on-target mechanisms that explain the increased risk for thrombosis
and viral infection or reactivation associated with JAK inhibitors, the observed elevated risk …

Magnesium plays a crucial role in many cell functions such as energy metabolism, protein
and DNA syntheses, and cytoskeleton activation. Proliferating cells have long been known …